CommercialAdministrativeLow impact
11.04.01e, Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)
Independence Blue Cross·Endocrinology·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of an existing policy covering islet cell transplantation including the use of Donislecel-jujn (Lantidra) for commercial plans. The policy was reposted with an effective date of April 1, 2026, maintaining current coverage guidelines for this specialized diabetes treatment.
Action Required
By April 1, 2026: Review current islet cell transplantation billing procedures to ensure compliance with reissued policy guidelines. Billing team should verify any coverage criteria or documentation requirements for Donislecel-jujn (Lantidra) treatments remain unchanged from previous policy version.